Page last updated: 2024-09-04

atrasentan and Carcinoma

atrasentan has been researched along with Carcinoma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Castelo, B; Espinosa, E; Merino, M; Pinto, A; Redondo, A; Zamora, P1
Carr, RA; Groenewegen, G; Humerickhouse, RA; Isaacson, JD; Janus, TJ; Leahy, TW; Voest, E; Zonnenberg, BA1
Carducci, M; Jimeno, A1

Reviews

2 review(s) available for atrasentan and Carcinoma

ArticleYear
Targeting the endothelin axis in prostate carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:2

    Topics: Atrasentan; Bone and Bones; Carcinoma; Cell Proliferation; Clinical Trials as Topic; Endothelins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines

2012
Atrasentan: targeting the endothelin axis in prostate cancer.
    Expert opinion on investigational drugs, 2004, Volume: 13, Issue:12

    Topics: Atrasentan; Carcinoma; Clinical Trials, Phase III as Topic; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A

2004

Trials

1 trial(s) available for atrasentan and Carcinoma

ArticleYear
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Atrasentan; Carcinoma; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Time Factors

2003